FEATURES OF THE PROFILE OF DRUG RESISTANCE TO FIRST-LINE ANTI-TUBERCULOSIS DRUGS IN PATIENTS WITH HIV INFECTION

The profile of drug resistance to anti-tuberculosis drugs in patients directly affects the course of the disease. However, a high percentage of multidrug resistance in patients with HIV infection not only worsens the course of the disease, but also forces the development of new tactics for managing such patients. The article discusses the characteristics of the profile of drug resistance to anti-tuberculosis drugs in patients with HIV infection using molecular genetic and bacteriological research methods. It is shown that for the period 2018-2022. the proportion of people infected with HIV who are resistant to isoniazid by 14.6% and rifampicin by 28.85%, by 717.39% to moxifloxacin and by 104.25% to amikacin has increased. The reduction in the choice of drugs and the possibility of effective anti-tuberculosis therapy in HIV-infected people is also complicated by the detection of a multidrug-resistant culture in 20.34% of the examined patients and multidrug resistance in 39.6% of patients. In addition, over a five-year period, the percentage of mutations in the genes of mycobacteria responsible for resistance to anti-tuberculosis drugs has increased. The necessity of finding new solutions in the prevention of the formation of resistance to existing anti-tuberculosis drugs, the development of new effective drugs for use as first-line and second-line drugs is substantiated.